Treatment options for juvenile-onset systemic lupus erythematosus

Pediatric Drugs

Volumn 4, Issue 4, 2002, Pages 241-256

  Carreño, Luis ^a   López Longo, Francisco Javier ^a   González, Carlos Manuel ^a   Monteagudo, Indalecio ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABETIMUS; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; AUTOANTIBODY; AZATHIOPRINE; BINDARIT; BROMOCRIPTINE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DAPSONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10 ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PRASTERONE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGY; ATHEROSCLEROSIS; B LYMPHOCYTE; BLOOD TOXICITY; BONE MARROW TRANSPLANTATION; DIFFERENTIAL DIAGNOSIS; GASTROINTESTINAL TOXICITY; GROWTH RETARDATION; HELPER CELL; HUMAN; HYPERTENSION; IMMUNE COMPLEX DISEASE; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; NAUSEA; PHOTOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THROMBOCYTOPENIA; VASCULITIS;

EID: 0036247651     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200204040-00004     Document Type: Review

References (134)

1. An overview of the pathogenesis of systemic lupus erythematosus
2. Systemic lupus erythematosus
3. Systemic lupus erythematosus: Pathogenesis
4. New environmental agents associated with lupus-like disorders
5. Role of T cell DNA methylation in lupus syndromes
6. Mechanism of autoimmune disease induction: The role of the immune response to microbial pathogens
7. The basis of autoimmunity (part 1): Mechanism of aberrant self-recognition
8. The apoptosis-1/Fas protein in human systemic lupus erythematosus
9. Impared polyclonal T cell cytolytic activity: A possible risk factor for systemic lupus erythematosus
10. The T cell enigma in lupus
11. Broken the dogma: Penetration of autoantibodies into living cells
12. Nucleosome: A major immunogen for pathogenic autoantibody-inducing T cells of lupus
13. Self-antigens and epitope spreading in systemic autoimmunity
14. Abnormalities of immunoregulation in juvenile rheumatoid arthritis
15. Abnormal T suppressor cell function in juvenile rheumatoid arthritis
16. Idiotype selection is an immunoregulatory mechanism which contributes to the pathogenesis of systemic lupus erythematosus
17. Immunoregulatory circuits and potential treatment of connective tissue diseases
18. Juvenile rheumatoid arthritis
19. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus
20. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus
21. Refractory nephrotic syndrome in lupus nephritis: Favorable response to indomethacin therapy
22. Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes syndrome
23. Treatment of lupus with corticosteroids
24. Local therapy for cutaneous and systemic lupus erythematosus: Practical and theoretical considerations
25. Dyslipoproteinemia in pediatric systemic lupus erythematosus
26. Lupus nephritis in children: A longitudinal study of prognostic factors and therapy
27. Treatment of lupus nephritis in children
28. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
29. Thrombosis and systemic lupus erythematosus: The Hopkins Lupus Cohort perspective
30. Premature atherosclerosis in systemic lupus erythematosus
31. Antimalarial therapy: A panacea for mild lupus?
32. Studies of immunosuppressive drugs in the treatment of lupus nephritis
33. Systemic lupus erythematosus in children
34. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs
35. Lupus nephritis in childhood and adolescence
36. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus
37. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus
38. Cyclophosphamide for the treatment of systemic lupus erythematosus
39. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy
40. Azathioprine therapy for patients with systemic lupus erythematosus
41. Immunosupressive drug use during pregnancy
42. What's new in the treatment of pediatric SLE
43. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis
44. The anti-inflammatory mechanism of methotrexate: Increased adenosine release at inflammed site diminishes leukocyte accumulation in an in vivo model of inflammation
45. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial
46. Methotrexate therapy in childhood systemic lupus erythematosus
47. Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus
48. Double-blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus
49. Methotrexate therapy in systemic lupus erythematosus
50. Tolerance of cyclosporine A in children with refractory juvenile chronic arthritis
51. Effect of low-dose cyclosporin A in the treatment of lupus nephritis in children
52. Clinical efficacy of cyclosporin A neoral in the treatment of paediatric lupus nephritis with heavy proteinuria
53. Cyclosporin-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus
54. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses
55. Update on therapy: Thalidomide in the treatment of lupus
56. Guideline for the clinical use and dispensing of thalidomide
57. A pilot study of 2 chloroxyadenosine (2-CdA) in the treatment of systemic lupus erythematosus associated glomerulonephritis
58. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus
59. Successful mofetil treatment of glomerular disease
60. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide
61. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: An open pilot trial
62. Mycophenolate mofetil for systemic lupus erythematosus
63. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations
64. Treatment of systemic lupus erythematosus with mycophenolate mofetil
65. Efficacy of mycophenolate mofetit in patients with diffuse proliferative lupus nephritis
66. Bindarit prolongs survival and reduces renal damage in NZB/W lupus mice
67. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease
68. Bindarit, a new potential therapeutic agent for lupus nephritis: A pilot study
69. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus
70. Danazol therapy for autoimmune hemolytic anemia
71. Danazol therapy in autoimmune hemolytic anemia associated with systemic lupus erythematosus
72. An open study of dehydroepiandrosterone in systemic lupus erythematosus
73. Dehydroepiandrosterone in systemic lupus erythematosus: Results of a double-blind, placebo-controlled, randomized clinical trial
74. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus
75. Prolactin influences autoimmune disease activity in the female B/W mouse
76. Bromocriptine immunomodulation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells
77. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus
78. Bromocriptine in systemic lupus erythematosus: A double blind, randomized placebo controlled study
79. Treatment of systemic lupus erythematosus with bromocriptine
80. UVA-1 cold light treatment of systemic lupus erythematosus: A double-blind, placebo controlled crossover trial
81. Plasma exchange in systemic lupus erythematosus
82. Randomized trial of plasma exchange in mild systemic lupus erythematosus
83. A randomized trial of plasma exchange in severe acute systemic lupus erythematosus: Methodology and interim analysis
84. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group
85. Systemic lupus erythematous: A case report with unusual manifestations and favourable outcome after plasmapheresis
86. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide
87. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group
88. The Lupus Plasmapheresis Study Group: Rationale and updated interim report
89. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis
90. Plasmapheresis in collagen vascular diseases
91. Therapeutic plasma exchange and cyclosporine in the treatment of systemic lupus erythematosus
92. Evaluation of adsorption selectivity dextran sulfate bound cellulose beads for the removal af anti-DNA antibodies
93. Clinical evaluation of immunoadsorption in patients with systemic lupus erythematosus using two dextran sulfate cellulose columns (SL-01, Selesorb) in an automated column regeneration unit
94. Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy
95. Catastrophic antiphospholipid syndrome: Response to repeated plasmapheresis over three years
96. The role of immunoadsorption using dextran-sulfate cellulose columns in the treatment of systemic lupus erythematosus
97. Thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus: Case report and literature review from the plasmapheresis era
98. The management of thrombosis in the anti-phospholipid-antibody syndrome
99. The catastrophic anti-phosphotipid syndrome
100. New therapies for systemic lupus erythematosus
101. High-dose intravenous immunoglobulins for lupus nephritis: A salvage immunomodulation
102. New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation
103. Affinity columns containing anti-DNA Id+ human myeloma proteins adsorb human epibodies from intravenous gamma globulin
104. Therapeutic preparations of normal poly-specified IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the fas apoptopic pathway
105. High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study
106. Intravenous immunogtobutin (IVIg) in the treatment of autoimmune diseases
107. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
108. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin
109. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis
110. Intravenous immunoglobulin treatment of lupus nephritis
111. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors
112. Intravenous immunoglobulin therapy: Magic or black magic
113. Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis
114. The CD40 ligand expressed by human B cells costimulates B cell responses
115. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC- 131) in patients with systemic lupus erythematosus
116. Idiotypic vaccination with a murine anti-dsDNA antibody: Phase I study in patients with nonactive systemic lupus erythematosus with nephritis
117. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis
118. Reduction in circulating dsDNA antibody titer after administration of LJP-394
119. Treatment of systemic lupus erythematosus with LJP 394
120. Clinical and pharmacological experience with LJP-394
121. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus
122. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus
123. Effect of recombinant erythropoietin therapy on autoimmunity in systemic lupus erythematosus
124. Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus
125. Anaemia in systemic lupus erythematosus: Aetiological profile and the role of erythropoietin
126. Decreased serum erythropoietin and its relation to anti-erythropoietin antibodies in anaemia of systemic lupus erythematosus
127. Stem cell transplantation in experimental models of autoimmune disease
128. Stem cell transplantation for severe autoimmune diseases: Progress and problems
129. Stem cell transplantation for treatment of severe autoimmune diseases: Current status and future perspectives
130. Prospects of stem cell transplantation in autoimmune diseases
131. Intense immune suppression for systemic lupus: The role of hematopoietic stem cells
132. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase I study
133. Immunoablation and haemopoietic stem cell transplantation for severe autoimmune disease with special reference to systemic lupus erythematosus